Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remdesivir - Gilead Sciences

Next Previous
Search
Drug Profile

Remdesivir - Gilead Sciences

Alternative Names: Captisol-enabled remdesivir; Captisol®-enabled GS 5734; GS-5734; Redyx; VEKLURY; Veklury

Latest Information Update: 28 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Capital Medical University; China-Japan Friendship Hospital; Chinese Academy of Medical Sciences; Dr Reddys Laboratories; Gilead Sciences; INSERM; National Institute of Allergy and Infectious Diseases; NeuroActiva; Roche
  • Class Adenine nucleotides; Amines; Antivirals; Esters; Furans; Nitriles; Phosphorus compounds; Pyridazines; Pyrroles; Small molecules; Triazines
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections
  • Phase III COVID-19 pneumonia
  • Phase II Ebola virus infections
  • No development reported Neurological disorders

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in COVID-2019-infections in New Zealand (IV, Infusion)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in COVID-2019-infections in Puerto Rico (IV, Infusion)
  • 11 Oct 2023 Efficacy data from a phase III REDPINE trial in Covid-19 infections presented at the IDWeek 2023 (IDW-2023)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top